Merck ($MRK) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: Thanks to cost-cutting initiatives, including laying off a projected 15,000 employees by 2012, Merck earned 85 cents per share this quarter. Its profits were dampened by a $950 million federal Vioxx fine. And despite growing generic competition for Cozaar and Hyzaar, its diabetes drugs Januvia and Janumet boosted sales 28 percent, and HIV drug Isentress rose 41 percent to $278 million. The company believes it will reach $3.31 to $3.39 earnings per share.

Highlights

  • Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income(1) for the third quarter was $342 million.

  • For the first nine months of 2010, worldwide sales were $33.9 billion and net income was $1.4 billion

See Merck's current stock quote from CNN Money

Merck's website: http://www.merck.com/
Full earnings release: Merck earnings release

Merck ($MRK) - Big Pharma's Q3 2010 Earnings Report
Read more on

Suggested Articles

Amarin Vascepa pill
Pharma

Amarin eyes blockbuster Vascepa sales with FDA label boost

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

by Kyle Blankenship
courthouse
Pharma

Gilead's Kite Pharma told to pay $752M for CAR-T infringement

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

by Eric Sagonowsky
Pfizer
Marketing

Pfizer's Xeljanz gets convenience boost with new XR formula

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

by Carly Helfand